Helsinn Group

Helsinn Group company information, Employees & Contact Information

Explore related pages

Related company profiles:

Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology, and dermato-oncology. Founded in 1976, Helsinn has nearly 50 years of experience in the pharmaceutical industry, with an extensive network of long-standing trusted partners enabling a commercial presence in about 150 countries. Helsinn Healthcare SA, headquartered in Lugano (Switzerland), oversees the activities of the three Helsinn Group’s subsidiaries (Helsinn Birex Pharmaceuticals Ltd., Helsinn Therapeutics (U.S.), Inc., Helsinn Pharmaceuticals (Beijing) Co., Ltd.), defining and implementing the Group’s strategy. Our mission is to champion and support patients with cancer and chronic diseases at every stage of their journey, by providing them with the best medications and solutions based on their needs and preferences. Follow our LinkedIn page to stay updated with news from Helsinn Group! If you are interested in joining us, please visit our website (www.helsinn.com): applications should only be submitted via the appropriate country portal, available under “Careers – Join us” website section. * This account shall only be used to share news concerning Helsinn. We would like to emphasize that due to the highly regulated nature of the pharma industry, we cannot engage with you online in any discussions concerning our or other companies’ products and/or services, and/or treatment options. It is best to hold such discussions and to seek guidance privately from your healthcare professional.

Company Details

Employees
367
Founded
-
Address
Via Pian Scairolo 9, Lugano/pazzallo,ticino 6912,switzerland
Phone
353 1 822 5404
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
Manager jobs.
HQ
Lugano/Pazzallo, Ticino
Looking for a particular Helsinn Group employee's phone or email?

Helsinn Group Questions

News

Personalised Antiemetic Prophylaxis with NEPA for Patients at High-Risk of Chemotherapy-induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: Results from the Randomised, Multinational MyRisk Trial - ScienceDirect.com

Personalised Antiemetic Prophylaxis with NEPA for Patients at High-Risk of Chemotherapy-induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: Results from the Randomised, Multinational MyRisk Trial ScienceDirect.com

Knight Therapeutics and Helsinn Healthcare SA Expand - GlobeNewswire

Knight Therapeutics and Helsinn Healthcare SA Expand GlobeNewswire

AKYNZEO® demonstrates superior prevention of chemotherapy-induced nausea and vomiting compared to the standard of care in patients receiving moderately emetogenic chemotherapy with additional predictive factors - The Manila Times

AKYNZEO® demonstrates superior prevention of chemotherapy-induced nausea and vomiting compared to the standard of care in patients receiving moderately emetogenic chemotherapy with additional predictive factors The Manila Times

Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico - GlobeNewswire

Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico GlobeNewswire

MD Anderson & Helsinn Healthcare SA partner to help patients conducting clinical studies in cancer care - MD Anderson Cancer Center

MD Anderson & Helsinn Healthcare SA partner to help patients conducting clinical studies in cancer care MD Anderson Cancer Center

Helsinn and Angelini Pharma renew AULIN and MESULID distribution deal - Pharmaceutical Technology

Helsinn and Angelini Pharma renew AULIN and MESULID distribution deal Pharmaceutical Technology

Supreme Court Decides Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. | Publications | Insights - Faegre Drinker Biddle & Reath LLP

Supreme Court Decides Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. | Publications | Insights Faegre Drinker Biddle & Reath LLP

SCOTUS Helsinn decision - Intellectual Property Alert - Nixon Peabody

SCOTUS Helsinn decision - Intellectual Property Alert Nixon Peabody

Helsinn Establishes New R&D Hub in the U.S. - Contract Pharma

Helsinn Establishes New R&D Hub in the U.S. Contract Pharma

Volunteer Voices: Allison Vavala, Helsinn, Chair of the DCAT Education Committee - DCAT Value Chain Insights

Volunteer Voices: Allison Vavala, Helsinn, Chair of the DCAT Education Committee DCAT Value Chain Insights

MEI Pharma, Helsinn Group cut losses, ditch phase 3 partnered cancer test for pracinostat - Fierce Biotech

MEI Pharma, Helsinn Group cut losses, ditch phase 3 partnered cancer test for pracinostat Fierce Biotech

BridgeBio, Helsinn Ink Up-to-$2.4B Infigratinib Partnership - Genetic Engineering and Biotechnology News

BridgeBio, Helsinn Ink Up-to-$2.4B Infigratinib Partnership Genetic Engineering and Biotechnology News

Available Now: New Toolkit Encourages Better Communication to Help Prevent Patients from Suffering in Silence Due to Chemotherapy-induced Nausea and Vomiting - PR Newswire

Available Now: New Toolkit Encourages Better Communication to Help Prevent Patients from Suffering in Silence Due to Chemotherapy-induced Nausea and Vomiting PR Newswire

Secret Sales Are Still Prior Art: U.S. Supreme Court Affirms Helsinn Healthcare - Jones Day

Secret Sales Are Still Prior Art: U.S. Supreme Court Affirms Helsinn Healthcare Jones Day

Ready-to-Dilute Liquid Formulation of Akynzeo Injection Approved - Medical Professionals Reference

Ready-to-Dilute Liquid Formulation of Akynzeo Injection Approved Medical Professionals Reference

Of Secret Sales and Public Uses: The Practical Consequences of the Supreme Court’s Helsinn Decision - IPWatchdog.com

Of Secret Sales and Public Uses: The Practical Consequences of the Supreme Court’s Helsinn Decision IPWatchdog.com

Helsinn Healthcare SA signs exclusive license agreement - GlobeNewswire

Helsinn Healthcare SA signs exclusive license agreement GlobeNewswire

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA® - GlobeNewswire

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA® GlobeNewswire

BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn - GlobeNewswire

BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn GlobeNewswire

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner - GlobeNewswire

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner GlobeNewswire

Akynzeo Now Included in NCCN Antiemesis Guidelines - Medical Professionals Reference

Akynzeo Now Included in NCCN Antiemesis Guidelines Medical Professionals Reference

Supreme Court decides Helsinn v. Teva, Secret Sale Qualifies as Prior Art Under the AIA - IPWatchdog.com

Supreme Court decides Helsinn v. Teva, Secret Sale Qualifies as Prior Art Under the AIA IPWatchdog.com

$2.4B BridgeBio/Helsinn Liver Cancer Deal Falls Apart - BioSpace

$2.4B BridgeBio/Helsinn Liver Cancer Deal Falls Apart BioSpace

CAFC Affirms ITC’s Invalidation of Sweetener Patent Under On-Sale Bar, Citing Helsinn - IPWatchdog.com

CAFC Affirms ITC’s Invalidation of Sweetener Patent Under On-Sale Bar, Citing Helsinn IPWatchdog.com

Helsinn and MEI Discontinue Phase III Trial of Pracinostat in AML - BioSpace

Helsinn and MEI Discontinue Phase III Trial of Pracinostat in AML BioSpace

Exclusive: Helsinn chief Riccardo Braglia spells out a blockbuster plan to take the family pharma public — with an eye on new cancer drug deals, spinout - Endpoints News

Exclusive: Helsinn chief Riccardo Braglia spells out a blockbuster plan to take the family pharma public — with an eye on new cancer drug deals, spinout Endpoints News

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile - Wiley Online Library

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile Wiley Online Library

Helsinn creates $50M VC fund to back early-stage cancer companies - Fierce Biotech

Helsinn creates $50M VC fund to back early-stage cancer companies Fierce Biotech

BridgeBio says it's undeterred after Truseltiq partner withdraws application, discontinues drug - Fierce Pharma

BridgeBio says it's undeterred after Truseltiq partner withdraws application, discontinues drug Fierce Pharma

Helsinn Advanced Synthesis Successfully Inspected by FDA - CHEManager

Helsinn Advanced Synthesis Successfully Inspected by FDA CHEManager

Helsinn Achieves Carbon Neutrality - Koreabizwire

Helsinn Achieves Carbon Neutrality Koreabizwire

Helsinn Presents Quality of Life, Its First Group Sustainability Report - PR Newswire UK

Helsinn Presents Quality of Life, Its First Group Sustainability Report PR Newswire UK

BridgeBio Pharma and Helsinn link up on novel GPX4 inhibitor - The Pharma Letter

BridgeBio Pharma and Helsinn link up on novel GPX4 inhibitor The Pharma Letter

Helsinn Advanced Synthesis Opens its Largest Dedicated Anticancer Bay - Koreabizwire

Helsinn Advanced Synthesis Opens its Largest Dedicated Anticancer Bay Koreabizwire

Industry Insiders: Opinions Mixed in Aftermath of Supreme Court Holding in Helsinn - IPWatchdog.com

Industry Insiders: Opinions Mixed in Aftermath of Supreme Court Holding in Helsinn IPWatchdog.com

Zealand, Helsinn’s GLP-2 cancer side effects drug flunks PhII - Fierce Biotech

Zealand, Helsinn’s GLP-2 cancer side effects drug flunks PhII Fierce Biotech

Juniper and Helsinn Partner to Bring Infigratinib to Emerging Markets - NAVLIN DAILY

Juniper and Helsinn Partner to Bring Infigratinib to Emerging Markets NAVLIN DAILY

Helsinn to acquire worldwide rights to Valchlor/Ledaga - The Pharma Letter

Helsinn to acquire worldwide rights to Valchlor/Ledaga The Pharma Letter

Helsinn Group, Actelion Pharma Enter Agreement - Contract Pharma

Helsinn Group, Actelion Pharma Enter Agreement Contract Pharma

Helsinn licenses BIAL for anamorelin distribution - The Pharma Letter

Helsinn licenses BIAL for anamorelin distribution The Pharma Letter

Helsinn Reaps Benefits of Cytotoxic Molecule Demand - CHEManager

Helsinn Reaps Benefits of Cytotoxic Molecule Demand CHEManager

Riccardo Braglia CEO & Group Vice Chairman of Helsinn - The CEO Magazine

Riccardo Braglia CEO & Group Vice Chairman of Helsinn The CEO Magazine

Swiss pharma group Helsinn announces €6m investment in Ireland - The Irish Times

Swiss pharma group Helsinn announces €6m investment in Ireland The Irish Times

Helsinn signs regional deal - pharmabiz.net

Helsinn signs regional deal pharmabiz.net

China Approves Mundipharma China/Helsinn Anti-Emetic Treatment - NAI500

China Approves Mundipharma China/Helsinn Anti-Emetic Treatment NAI500

Glenmark Pharmaceuticals and Helsinn Group to launch AKYNZEO in India and Nepal - Express Pharma

Glenmark Pharmaceuticals and Helsinn Group to launch AKYNZEO in India and Nepal Express Pharma

Top Helsinn Group Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant